{"success":true,"data":{"pressRelease":{"id":"4627","rtpr_id":"nPn3WfTYpa","ticker":"SERA","exchange":"NASDAQ","all_tickers":["SERA"],"title":"SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF FIRST QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON MAY 6, 2026","author":"PR Newswire","published_at":"2026-04-22T12:05:00.015Z","article_body":"SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF FIRST QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON MAY 6, 2026\n\nPR Newswire\n\nSALT LAKE CITY, April 22, 2026\n\nSALT LAKE CITY, April 22, 2026 /PRNewswire/ -- Sera Prognostics Inc.\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4670313-1&h=4223806969&u=https%3A%2F%2Fwww.sera.com%2F&a=Sera+Prognostics+Inc.)\n, The Pregnancy Company(®) (Nasdaq: SERA), focused on improving maternal and\nneonatal health by providing innovative pregnancy biomarker information to\ndoctors and patients, today announced it will report first quarter fiscal year\n2026 financial results on Wednesday May 6, 2026, after the close of the\nmarket. The Company will host a corresponding conference call and live webcast\nto discuss operational highlights, financial results and key topics at 5:00\np.m. Eastern Time. A press release outlining the financial results and\nhighlights will be publicly distributed before the call.\n\n(https://mma.prnewswire.com/media/2687539/Sera_Prognostics_Logo.html)\n\nConference Call Details:\n\nUS domestic callers: (800) 836-8184\n\nInternational callers: (646) 357-8785\n\nWebcast Registration Link: https://app.webinar.net/voeWlGmwyd6\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4670313-1&h=3397446513&u=https%3A%2F%2Fapp.webinar.net%2FvoeWlGmwyd6&a=https%3A%2F%2Fapp.webinar.net%2FvoeWlGmwyd6)\n\nLive audio of the webcast will be available online from the Investors page of\nthe Company's website at www.sera.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4670313-1&h=4027492518&u=http%3A%2F%2Fwww.sera.com%2F&a=www.sera.com)\n. The webcast will be archived on the Investors page and will be available for\none year.\n\nAbout Sera Prognostics, Inc.\n\nSera Prognostics is a leading health diagnostics company dedicated to\nimproving the lives of women and babies through precision pregnancy care.\nSera's mission is to provide early, pivotal pregnancy information to improve\nthe health of mothers and newborns, resulting in reductions in the costs of\nhealthcare delivery. Sera has a robust pipeline of innovative diagnostic tests\nfocused on the early prediction of preterm birth risk and other complications\nof pregnancy. Sera's precision medicine PreTRM(®) Test reports to a physician\nthe individualized risk of spontaneous premature delivery in a pregnancy,\nenabling earlier proactive interventions in women with higher risk. Sera\nPrognostics is headquartered in Salt Lake City, Utah.\n\nAbout Preterm Birth\n\nPreterm birth is defined as any birth before 37 weeks' gestation and is the\nleading cause of illness and death in newborns. The 2025 March of Dimes\nReport Card shows that, for the fourth consecutive year, the United\nStates earned a D+ grade for preterm birth, making the longest stretch of the\nlowest grade in Report Card history. Prematurity is associated with a\nsignificantly increased risk of major long-term medical complications,\nincluding learning disabilities, cerebral palsy, chronic respiratory illness,\nintellectual disability, seizures, and vision and hearing loss, and can\ngenerate significant costs throughout the lives of affected children. The\nannual health care costs to manage short- and long-term complications of\nprematurity in the United States were estimated to be approximately\n$25 billion for 2016.\n\nAbout the PreTRM(®) Test\n\nThe PreTRM(®) Test is the only broadly validated, commercially available\nblood-based biomarker test that provides an early, accurate and individualized\nrisk prediction for spontaneous preterm birth in asymptomatic singleton\npregnancies. The PreTRM(®) Test measures and analyzes proteins in the blood\nthat are highly predictive of preterm birth. The PreTRM(®) Test permits\nphysicians to identify, during the weeks 18 through 20 of pregnancy, which\nwomen are at increased risk for preterm birth and its complications, enabling\nmore informed, personalized clinical decisions based on each woman's\nindividual risk. The PreTRM(®) Test is ordered by a medical professional.\n\nSera, Sera Prognostics, the Sera Prognostics logo, The Pregnancy Company, and\nPreTRM are trademarks or registered trademarks of Sera Prognostics, Inc. in\nthe United States and/or other countries.\n\nSafe Harbor Statement\n\nThis press release contains \"forward-looking statements\" within the meaning of\nthe Private Securities Litigation Reform Act of 1995, including statements\nrelating to the date and time and content of the Company's quarterly earnings\nrelease and conference call; availability of the live audio of the conference\ncall on the Company's website; and the Company's strategic directives under\nthe caption \"About Sera Prognostics, Inc.\" These \"forward-looking statements\"\nare based on management's current expectations of future events and are\nsubject to a number of risks and uncertainties that could cause actual results\nto differ materially and adversely from those set forth in or implied by\nforward-looking statements. These risks and uncertainties include, but are not\nlimited to: net losses, cash generation, and the potential need to raise more\ncapital; revenues from the PreTRM Test representing substantially all Company\nrevenues to date; the need for broad scientific and market acceptance of the\nPreTRM Test; a concentrated number of material customers; our ability to\nintroduce new products; potential competition; our proprietary biobank;\ncritical suppliers; estimates of total addressable market opportunity and\nforecasts of market growth; potential third-party payer coverage and\nreimbursement; new reimbursement methodologies applicable to the PreTRM Test,\nincluding new CPT codes and payment rates for those codes; changes in FDA\nregulation of laboratory-developed tests; the intellectual property rights\nprotecting our tests and market position; and other factors discussed under\nthe heading \"Risk Factors\" contained in our Annual Report on Form 10-K and\nQuarterly Reports on Form 10-Q filed with the Securities and Exchange\nCommission, as well as any updates to those risk factors filed from time to\ntime in our periodic and current reports filed with the Securities and\nExchange Commission. All information in this press release is as of the date\nof the release, and the Company undertakes no duty to update this information\nunless required by law.\n\nInvestor Contact\nJennifer Zibuda, Head of Investor Relations\njzibuda@sera.com (mailto:jzibuda@sera.com)\n+1 (801) 396-8043\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/sera-prognostics-announces-conference-call-and-webcast-of-first-quarter-fiscal-year-2026-financial-results-on-may-6-2026-302749482.html\n(https://www.prnewswire.com/news-releases/sera-prognostics-announces-conference-call-and-webcast-of-first-quarter-fiscal-year-2026-financial-results-on-may-6-2026-302749482.html)\n\nSOURCE Sera Prognostics, Inc.\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2687539/Sera_Prognostics_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn3WfTYpa","title":"SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF FIRST QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON MAY 6, 2026","author":"PR Newswire","ticker":"SERA","created":"2026-04-22T12:05:00.015Z","tickers":["SERA"],"exchange":"NASDAQ","article_body":"SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF FIRST QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON MAY 6, 2026\n\nPR Newswire\n\nSALT LAKE CITY, April 22, 2026\n\nSALT LAKE CITY, April 22, 2026 /PRNewswire/ -- Sera Prognostics Inc.\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4670313-1&h=4223806969&u=https%3A%2F%2Fwww.sera.com%2F&a=Sera+Prognostics+Inc.)\n, The Pregnancy Company(®) (Nasdaq: SERA), focused on improving maternal and\nneonatal health by providing innovative pregnancy biomarker information to\ndoctors and patients, today announced it will report first quarter fiscal year\n2026 financial results on Wednesday May 6, 2026, after the close of the\nmarket. The Company will host a corresponding conference call and live webcast\nto discuss operational highlights, financial results and key topics at 5:00\np.m. Eastern Time. A press release outlining the financial results and\nhighlights will be publicly distributed before the call.\n\n(https://mma.prnewswire.com/media/2687539/Sera_Prognostics_Logo.html)\n\nConference Call Details:\n\nUS domestic callers: (800) 836-8184\n\nInternational callers: (646) 357-8785\n\nWebcast Registration Link: https://app.webinar.net/voeWlGmwyd6\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4670313-1&h=3397446513&u=https%3A%2F%2Fapp.webinar.net%2FvoeWlGmwyd6&a=https%3A%2F%2Fapp.webinar.net%2FvoeWlGmwyd6)\n\nLive audio of the webcast will be available online from the Investors page of\nthe Company's website at www.sera.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4670313-1&h=4027492518&u=http%3A%2F%2Fwww.sera.com%2F&a=www.sera.com)\n. The webcast will be archived on the Investors page and will be available for\none year.\n\nAbout Sera Prognostics, Inc.\n\nSera Prognostics is a leading health diagnostics company dedicated to\nimproving the lives of women and babies through precision pregnancy care.\nSera's mission is to provide early, pivotal pregnancy information to improve\nthe health of mothers and newborns, resulting in reductions in the costs of\nhealthcare delivery. Sera has a robust pipeline of innovative diagnostic tests\nfocused on the early prediction of preterm birth risk and other complications\nof pregnancy. Sera's precision medicine PreTRM(®) Test reports to a physician\nthe individualized risk of spontaneous premature delivery in a pregnancy,\nenabling earlier proactive interventions in women with higher risk. Sera\nPrognostics is headquartered in Salt Lake City, Utah.\n\nAbout Preterm Birth\n\nPreterm birth is defined as any birth before 37 weeks' gestation and is the\nleading cause of illness and death in newborns. The 2025 March of Dimes\nReport Card shows that, for the fourth consecutive year, the United\nStates earned a D+ grade for preterm birth, making the longest stretch of the\nlowest grade in Report Card history. Prematurity is associated with a\nsignificantly increased risk of major long-term medical complications,\nincluding learning disabilities, cerebral palsy, chronic respiratory illness,\nintellectual disability, seizures, and vision and hearing loss, and can\ngenerate significant costs throughout the lives of affected children. The\nannual health care costs to manage short- and long-term complications of\nprematurity in the United States were estimated to be approximately\n$25 billion for 2016.\n\nAbout the PreTRM(®) Test\n\nThe PreTRM(®) Test is the only broadly validated, commercially available\nblood-based biomarker test that provides an early, accurate and individualized\nrisk prediction for spontaneous preterm birth in asymptomatic singleton\npregnancies. The PreTRM(®) Test measures and analyzes proteins in the blood\nthat are highly predictive of preterm birth. The PreTRM(®) Test permits\nphysicians to identify, during the weeks 18 through 20 of pregnancy, which\nwomen are at increased risk for preterm birth and its complications, enabling\nmore informed, personalized clinical decisions based on each woman's\nindividual risk. The PreTRM(®) Test is ordered by a medical professional.\n\nSera, Sera Prognostics, the Sera Prognostics logo, The Pregnancy Company, and\nPreTRM are trademarks or registered trademarks of Sera Prognostics, Inc. in\nthe United States and/or other countries.\n\nSafe Harbor Statement\n\nThis press release contains \"forward-looking statements\" within the meaning of\nthe Private Securities Litigation Reform Act of 1995, including statements\nrelating to the date and time and content of the Company's quarterly earnings\nrelease and conference call; availability of the live audio of the conference\ncall on the Company's website; and the Company's strategic directives under\nthe caption \"About Sera Prognostics, Inc.\" These \"forward-looking statements\"\nare based on management's current expectations of future events and are\nsubject to a number of risks and uncertainties that could cause actual results\nto differ materially and adversely from those set forth in or implied by\nforward-looking statements. These risks and uncertainties include, but are not\nlimited to: net losses, cash generation, and the potential need to raise more\ncapital; revenues from the PreTRM Test representing substantially all Company\nrevenues to date; the need for broad scientific and market acceptance of the\nPreTRM Test; a concentrated number of material customers; our ability to\nintroduce new products; potential competition; our proprietary biobank;\ncritical suppliers; estimates of total addressable market opportunity and\nforecasts of market growth; potential third-party payer coverage and\nreimbursement; new reimbursement methodologies applicable to the PreTRM Test,\nincluding new CPT codes and payment rates for those codes; changes in FDA\nregulation of laboratory-developed tests; the intellectual property rights\nprotecting our tests and market position; and other factors discussed under\nthe heading \"Risk Factors\" contained in our Annual Report on Form 10-K and\nQuarterly Reports on Form 10-Q filed with the Securities and Exchange\nCommission, as well as any updates to those risk factors filed from time to\ntime in our periodic and current reports filed with the Securities and\nExchange Commission. All information in this press release is as of the date\nof the release, and the Company undertakes no duty to update this information\nunless required by law.\n\nInvestor Contact\nJennifer Zibuda, Head of Investor Relations\njzibuda@sera.com (mailto:jzibuda@sera.com)\n+1 (801) 396-8043\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/sera-prognostics-announces-conference-call-and-webcast-of-first-quarter-fiscal-year-2026-financial-results-on-may-6-2026-302749482.html\n(https://www.prnewswire.com/news-releases/sera-prognostics-announces-conference-call-and-webcast-of-first-quarter-fiscal-year-2026-financial-results-on-may-6-2026-302749482.html)\n\nSOURCE Sera Prognostics, Inc.\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2687539/Sera_Prognostics_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-04-22T12:05:00.080992416Z","server_sent_at_ms":1776859500080},"received_at":"2026-04-22T12:05:00.134Z","source_url":null},"analysis":{"id":"3259","press_release_id":"4627","analysis_json":{"industry":{"label":"Health Care Equipment & Services","sector":"Health Care"},"redFlags":[],"eventType":"earnings","narrative":"Sera Prognostics announced it will report its first quarter fiscal year 2026 financial results on Wednesday, May 6, 2026, after the market closes.\n\nThe company will host a conference call and live webcast at 5:00 p.m. Eastern Time to discuss operational highlights and financial performance.\n\nSera specializes in pregnancy biomarker diagnostics, offering the PreTRM Test for early prediction of preterm birth risk.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":""},"keyFigures":{},"namedEntities":{"people":[{"name":"Jennifer Zibuda","role":"Head of Investor Relations"}],"products":["PreTRM Test"],"companies":[{"name":"Sera Prognostics, Inc.","ticker":"SERA"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine announcement of an earnings date and conference call with no financial results or guidance disclosed."},"tickerRelevance":{"others":[],"primary":"SERA"},"eventTypeSecondary":[]},"event_type":"earnings","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Sera Prognostics announced it will report its first quarter fiscal year 2026 financial results on Wednesday, May 6, 2026, after the market closes.\n\nThe company will host a conference call and live webcast at 5:00 p.m. Eastern Time to discuss operational highlights and financial performance.\n\nSera specializes in pregnancy biomarker diagnostics, offering the PreTRM Test for early prediction of preterm birth risk.","key_figures":{},"named_entities":{"people":[{"name":"Jennifer Zibuda","role":"Head of Investor Relations"}],"products":["PreTRM Test"],"companies":[{"name":"Sera Prognostics, Inc.","ticker":"SERA"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:2f2748f0fcc8c4f2","schema_hash":"sha256:ad96b863d7123008","created_at":"2026-04-22T15:14:17.067Z","global_importance":3,"audience_relevance":3,"importance_components":{"method":"backfill-heuristic","signals":{"bodyLong":false,"headlineTier1":false,"tickerCovered":false,"hadSignificance":false},"version":1,"computedAt":"2026-04-27T11:52:54.139Z"}},"durationMs":42540,"modelName":"glm-4.7"}}